Tresiba Geriatric (65+) Caregiver Administration Guidance

Why Insulin Degludec Is Often Chosen for Older Adults

Insulin degludec carries several pharmacokinetic properties that make it a practical choice for elderly patients who depend on caregiver support. The ultra-long half-life of roughly 25 hours produces a flat, peakless action profile that reduces the moment-to-moment variability in blood glucose that contributes to unexpected hypoglycemia events [1]. Compared to insulin glargine U-100, degludec reaches steady state in approximately 3 to 4 days, which means dose adjustments produce gradual rather than abrupt changes in overnight glucose [2].

Caregivers benefit from this stability. A missed or delayed injection does not create the same acute risk as with intermediate-acting insulins such as NPH, and the 8-hour timing window (discussed below) reduces scheduling pressure in households where routines shift.

Pharmacokinetic Advantages Relevant to Geriatric Care

The Endocrine Society's 2019 clinical practice guideline on diabetes management in older adults specifically notes that basal insulins with flatter profiles reduce hypoglycemia risk compared to NPH or pre-mixed formulations in this population [3]. Degludec's coefficient of variation for glucose-lowering effect is approximately 20%, versus roughly 82% for NPH insulin, according to pharmacodynamic crossover data published in Diabetes Care [4].

Renal function declines in a substantial proportion of adults over 65. The FDA prescribing information for Tresiba notes that no dose adjustment is required based on renal impairment alone, but clinical judgment is needed because reduced kidney function can prolong insulin action and increase hypoglycemia risk [1]. Caregivers should ask the prescribing clinician to review kidney function labs (eGFR, serum creatinine) at least annually.

What the DEVOTE Trial Showed

The DEVOTE trial (N=7,637, mean age 65.0 years) compared degludec to glargine U-100 in high-cardiovascular-risk patients with type 2 diabetes over a median follow-up of 2.0 years. Degludec produced a 40% lower rate of severe hypoglycemia (1.48 vs. 2.46 events per patient-year, P<0.001) and a 53% reduction in nocturnal severe hypoglycemia compared to glargine U-100 [5]. For caregivers who are not present overnight, that reduction in nocturnal events carries direct safety meaning.

Caregiver Injection Technique: Step-by-Step

Correct injection technique is the single most modifiable factor in insulin therapy outcomes for older adults receiving caregiver-administered doses. Errors in site selection, needle length, and air-shot priming account for a large share of dosing inaccuracies documented in clinical audits [6].

Preparing the FlexTouch Pen

The Tresiba FlexTouch pen is a prefilled, disposable device. Caregivers should follow these steps before every injection [1]:

1. Wash hands with soap and water for at least 20 seconds.
2. Inspect the cartridge window. Insulin degludec should appear clear and colorless. Do not use a cloudy, discolored, or particle-containing pen.
3. Attach a new NovoFine or compatible needle by pushing and twisting until secure.
4. Turn the dose selector to the flow-check symbol (2 units) and press the dose button until "0" appears. A drop of insulin at the needle tip confirms the pen is primed. Repeat if no drop appears.
5. Select the prescribed dose by rotating the selector until the correct number appears in the dose window.

The FlexTouch requires a push force approximately 70% lower than conventional insulin pens, a design feature that benefits older adults or caregivers managing hand strength limitations [7].

Injection Site Selection and Rotation

Approved injection sites are the abdomen, upper arm (outer portion), and thigh. Abdomen is generally preferred for basal insulin in older adults because absorption variability is lower than the thigh [8]. Caregivers should rotate within a single region, moving the injection point at least 1 cm from the previous site to reduce lipohypertrophy, a complication documented in 30% to 50% of insulin users in one systematic review (N=7,695 across 24 studies) and associated with erratic absorption and increased total daily insulin dose [9].

Needle Length and Angle

A 4 mm needle inserted at 90 degrees is recommended for most adults, including older patients, per the 2016 Diabetes Technology and Therapeutics consensus on injection technique [10]. For patients with very low subcutaneous fat (common in frail elderly individuals), a skin-lifted technique or slightly angled insertion may be appropriate. Intramuscular injection increases absorption speed unpredictably and raises hypoglycemia risk.

Post-Injection Steps

Hold the needle in place for at least 6 seconds after pressing the dose button fully. This prevents insulin from leaking back through the needle channel, which can cause a 5% to 30% dose loss according to injection technique data cited in the Diabetes Technology and Therapeutics consensus [10]. Remove the needle, cap it using the outer shield, and dispose of it in an approved sharps container. Never recap with two hands.

Dosing the Geriatric Patient: What Caregivers Need to Know

Caregivers do not set insulin doses, but they must understand the prescribed regimen well enough to identify errors, recognize when circumstances warrant a call to the prescriber, and administer the dose as ordered. The FDA-approved starting dose for insulin-naive adults with type 2 diabetes is 10 units once daily or 0.1 to 0.2 units per kg once daily [1].

Dose Titration Principles

The ADA Standards of Medical Care in Diabetes 2024 recommends titrating basal insulin by 2 units every 3 days (a "2-2-3" approach or similar algorithm) to reach a fasting glucose target of 80 to 130 mg/dL [11]. For older adults, the ADA recommends individualized targets: a fasting glucose of 80 to 180 mg/dL may be appropriate for patients with multiple comorbidities, cognitive impairment, or limited life expectancy [11].

The prescriber sets these targets. Caregivers should record fasting morning glucose readings daily and report trends (three or more consecutive readings above or below target) to the clinical team rather than adjusting doses independently.

The 8-Hour Dosing Window

One of degludec's most caregiver-relevant properties is its flexible dosing interval. The FDA prescribing information states that Tresiba may be administered at any time of day, provided that consecutive injections are at least 8 hours apart [1]. For a patient who normally takes their dose at 8:00 PM, an acceptable range spans from noon to midnight. This flexibility accommodates caregiver schedule variability without compromising glycemic control, a property documented in the FLEX trial, which showed no significant difference in HbA1c or hypoglycemia rate between fixed and flexible dosing schedules [12].

Insulin-to-Insulin Transitions

When a patient transitions from another basal insulin to degludec, the conversion ratio matters. Switching from glargine U-100 or detemir is typically done unit-for-unit, while switching from NPH may require a 20% dose reduction to account for degludec's more potent and prolonged effect [1]. Caregivers should confirm the exact conversion instructions in writing from the prescriber before the first degludec dose.

Hypoglycemia Recognition and Response in Older Adults

Hypoglycemia is the most dangerous acute complication of insulin therapy. Older adults face compounded risk: blunted adrenergic symptoms (sweating, tremor, palpitations) due to autonomic neuropathy or beta-blocker use, cognitive effects that impair self-recognition, and a lower physiologic glucose counterregulatory response [13].

Symptom Recognition for Caregivers

The ADA defines clinically significant hypoglycemia as a blood glucose below 54 mg/dL (Level 2), and severe hypoglycemia as any event requiring external assistance [11]. In older adults, hypoglycemia may present atypically as confusion, sudden behavioral change, weakness, or falls rather than classic sweating and tremor [13]. Caregivers should treat any unexplained acute change in mental status as a possible hypoglycemic event until a glucose reading confirms otherwise.

The 15-15 Rule

The ADA recommends the "15-15 rule" for conscious patients with glucose below 70 mg/dL: consume 15 grams of fast-acting carbohydrate, wait 15 minutes, and recheck glucose [11]. Appropriate sources include 4 glucose tablets, 4 ounces (120 mL) of orange juice, or 1 tube of glucose gel. Do not give food or liquid to a patient who is unconscious or unable to swallow safely. For severe hypoglycemia, inject 1 mg glucagon intramuscularly or intranasally (nasal glucagon 3 mg, FDA-approved as Baqsimi) and call emergency services immediately [14].

When to Call the Prescriber

Caregivers should contact the clinical team promptly if: blood glucose falls below 70 mg/dL on two or more occasions within one week, if a severe episode requiring third-party assistance occurs, or if fasting glucose is consistently above 250 mg/dL for three consecutive days. These thresholds align with ADA monitoring guidance and indicate the need for a dose or regimen review [11].

Storage, Handling, and Device Options

Proper storage preserves insulin potency. Degraded insulin produces unpredictable glycemic control and is a common, underappreciated source of caregiver-related dosing errors documented in real-world audits [6].

Storage Requirements

Unopened Tresiba pens and vials should be refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light. Freezing destroys insulin structure; discard any pen or vial that has been frozen [1]. In-use pens should be stored at room temperature, below 30°C (86°F), away from direct heat and light. Discard in-use pens after 56 days regardless of remaining insulin volume, per FDA labeling [1].

Caregivers managing multiple medications should use a small labeled container or zip-lock bag to segregate the in-use Tresiba pen from refrigerated stock, preventing confusion and accidental freezing of a room-temperature pen.

Available Formulations

Tresiba is available in two concentrations [1]:

• Tresiba 100 U/mL: FlexTouch pens (3 mL, max 80 units/dose) and 10 mL vials.
• Tresiba 200 U/mL: FlexTouch pens (3 mL, max 160 units/dose) in a grey-capped pen distinct from the 100 U/mL red cap.

The 200 U/mL formulation delivers the same number of units in half the injection volume, which may reduce injection discomfort in patients requiring large doses. Caregivers must confirm which concentration is prescribed before administering. Confusing concentrations is a serious medication error: administering 200 U/mL when 100 U/mL is prescribed doubles the intended dose.

Devices for Patients with Visual or Dexterity Impairment

For patients with visual impairment, the FlexTouch pen dose window includes tactile clicks audible during dose selection, with each click representing 1 unit (100 U/mL pen) or 2 units (200 U/mL pen). A talking blood glucose meter or a bright-contrast glucometer display supports independent glucose monitoring between caregiver visits [15]. Caregivers managing patients with severe dexterity limitations may request a pen needle removal device from the pharmacy or diabetes educator.

Monitoring Parameters Caregivers Should Track

Structured monitoring data gives the prescribing clinician the information needed to adjust therapy safely. Caregivers who collect and organize this data reduce the lag time between a glycemic problem and a clinical response [11].

Blood Glucose Monitoring

For patients on basal insulin only (no mealtime insulin), fasting morning glucose is the primary monitoring target. Caregivers should record time, glucose value, any symptoms, and notable circumstances (illness, missed meal, change in activity) in a logbook or phone-based diabetes app. The ADA recommends that patients on insulin monitor as often as their regimen requires and their prescriber directs [11].

HbA1c and Lab Monitoring

HbA1c should be checked at least twice yearly in stable patients and quarterly when glycemic control is changing or a dose adjustment has recently been made [11]. Renal function (eGFR and creatinine) should be checked at least annually in all patients with diabetes, and more frequently when eGFR falls below 60 mL/min/1.73 m2, because worsening kidney function may signal the need to reduce the degludec dose or simplify the regimen [16].

Injection Site Assessment

At each home visit, caregivers should inspect injection sites for lipohypertrophy (firm, rubbery lumps under the skin) or lipoatrophy (depressions in the skin). Injecting into a lipohypertrophic area reduces absorption by up to 25% in some patients and contributes to unexplained hyperglycemia [9]. Rotate away from affected sites and report persistent lipohypertrophy to the clinical team.

Special Circumstances in Geriatric Insulin Management

Illness and Sick-Day Rules

Illness increases insulin resistance, and blood glucose often rises even when a patient is eating poorly. Caregivers should never discontinue basal insulin during illness without explicit prescriber instruction, because doing so risks diabetic ketoacidosis in type 1 patients and severe hyperglycemia in type 2 patients [17]. The American Diabetes Association recommends checking glucose every 4 hours during acute illness and contacting the clinical team if glucose exceeds 300 mg/dL or if ketones are detected [17].

Cognitive Impairment and Caregiver Supervision

An estimated 20% to 30% of older adults with diabetes have comorbid cognitive impairment, according to a meta-analysis of 14 cohort studies published in Diabetes Care [18]. Cognitive impairment raises the risk of insulin omission, double-dosing, and failure to recognize hypoglycemia. Caregivers in these situations should administer insulin directly rather than prompting the patient, keep pens and sharps in a locked storage area, and consider a daily administration checklist reviewed by the clinical team at each visit [18].

Frailty and Reduced Appetite

Frail older adults with poor or unpredictable oral intake face higher hypoglycemia risk from fixed basal insulin doses. In these patients, the prescriber may target a higher fasting glucose range (for example, 100 to 200 mg/dL) and prescribe a lower starting dose. Caregivers should report any meal skipping or significant reduction in food intake on the same day it occurs, as this changes the risk-benefit ratio of that day's insulin dose [3].

Caregiver Competency: Training Requirements and Resources

A caregiver who has never administered insulin should receive hands-on training from a certified diabetes care and education specialist (CDCES) or a diabetes-experienced registered nurse before administering Tresiba independently. Self-directed reading alone is insufficient for safe insulin administration [19].

Key Training Milestones

The Association of Diabetes Care and Education Specialists recommends that insulin-administering caregivers demonstrate competency in: pen priming, site selection and rotation, correct needle length and angle, post-injection needle removal and disposal, and hypoglycemia recognition and response [19]. Training should be documented in the patient's care plan.

Manufacturer and Payer Resources

Novo Nordisk (Tresiba's manufacturer) provides a patient support program that may supply FlexTouch demonstration pens and injection technique videos. The NeedyMeds database and the Novo Nordisk Patient Assistance Program offer cost-support pathways for uninsured or underinsured patients. Caregivers should also ask the clinical team for a referral to a CDCES-led diabetes self-management education and support (DSMES) program, which Medicare covers under benefit code G0108 or G0109 [20].